What happened

Shares of Moderna (NASDAQ:MRNA) climbed 6.2% on Tuesday on a bevy of good news for the biotechnology company.

So what

Swiss health regulators authorized Moderna's COVID-19 vaccine for use in the country. The Swiss Federal Government subsequently ordered 7.5 million doses of the vaccine, with the first deliveries expected to start later this month. 

A person is pointing to an upwardly sloping digital stock chart.

Moderna's stock popped on Tuesday after several promising developments. Image source: Getty Images.

Moderna also announced a collaboration with Uber Technologies (NYSE:UBER) to boost awareness of and access to its coronavirus vaccine. Uber will share vaccine safety information through its app. The two companies are also evaluating how to more seamlessly integrate ride scheduling into vaccine appointment services. 

"Used by millions of people every day, the Uber platform can both help educate the public about vaccine safety and help eliminate transportation barriers to vaccination," Uber CEO Dara Khosrowshahi said in a press release.

Now what 

Better still, Moderna said on Monday it expects immunity from its coronavirus vaccine to last for at least one year. The biotech is also hopeful that its vaccine will prove effective against new strains of the virus, though it is still conducting tests to confirm whether this is true. 

Looking ahead, CEO Stéphane Bancel expects Moderna to deliver up to 1 billion doses -- and generate as much as $11.7 billion in vaccine sales -- in 2021. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.